These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 38240416)
1. In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis. Schuster J; Dreyhaupt J; Mönkemöller K; Dupuis L; Dieterlé S; Weishaupt JH; Kassubek J; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Johannesen S; Göricke B; Witzel S; Dorst J; Ludolph AC; Eur J Neurol; 2024 Apr; 31(4):e16204. PubMed ID: 38240416 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B; Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198 [TBL] [Abstract][Full Text] [Related]
3. Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Statland JM; Moore D; Wang Y; Walsh M; Mozaffar T; Elman L; Nations SP; Mitsumoto H; Fernandes JA; Saperstein D; Hayat G; Herbelin L; Karam C; Katz J; Wilkins HM; Agbas A; Swerdlow RH; Santella RM; Dimachkie MM; Barohn RJ; Muscle Nerve; 2019 Feb; 59(2):201-207. PubMed ID: 30192007 [TBL] [Abstract][Full Text] [Related]
4. A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement. Macchi Z; Wang Y; Moore D; Katz J; Saperstein D; Walk D; Simpson E; Genge A; Bertorini T; Fernandes JA; Swenson A; Elman L; Dimachkie M; Herbelin L; Miller J; Lu J; Wilkins H; Swerdlow RH; Statland J; Barohn R; Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(5-6):345-52. PubMed ID: 25832828 [TBL] [Abstract][Full Text] [Related]
5. Longitudinal course of neurofilament light chain levels in amyotrophic lateral sclerosis-insights from a completed randomized controlled trial with rasagiline. Witzel S; Statland JM; Steinacker P; Otto M; Dorst J; Schuster J; Barohn RJ; Ludolph AC Eur J Neurol; 2024 Mar; 31(3):e16154. PubMed ID: 37975796 [TBL] [Abstract][Full Text] [Related]
6. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease. Abdul Wahid SF; Law ZK; Ismail NA; Lai NM Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962 [TBL] [Abstract][Full Text] [Related]
7. Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis. Andrews JA; Meng L; Kulke SF; Rudnicki SA; Wolff AA; Bozik ME; Malik FI; Shefner JM JAMA Neurol; 2018 Jan; 75(1):58-64. PubMed ID: 29181534 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. ; Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181 [TBL] [Abstract][Full Text] [Related]
9. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial. Lombardo FL; Spila Alegiani S; Mayer F; Cipriani M; Lo Giudice M; Ludolph AC; McDermott CJ; Corcia P; Van Damme P; Van den Berg LH; Hardiman O; Nicolini G; Vanacore N; Dickie B; Albanese A; Puopolo M; Trials; 2023 Dec; 24(1):792. PubMed ID: 38053196 [TBL] [Abstract][Full Text] [Related]
15. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Cudkowicz ME; Lindborg SR; Goyal NA; Miller RG; Burford MJ; Berry JD; Nicholson KA; Mozaffar T; Katz JS; Jenkins LJ; Baloh RH; Lewis RA; Staff NP; Owegi MA; Berry DA; Gothelf Y; Levy YS; Aricha R; Kern RZ; Windebank AJ; Brown RH Muscle Nerve; 2022 Mar; 65(3):291-302. PubMed ID: 34890069 [TBL] [Abstract][Full Text] [Related]
16. Effect of mesenchymal stromal cell transplantation on long-term survival in amyotrophic lateral sclerosis. De Marchi F; Mareschi K; Ferrero I; Cantello R; Fagioli F; Mazzini L Cytotherapy; 2023 Aug; 25(8):798-802. PubMed ID: 36931995 [TBL] [Abstract][Full Text] [Related]
17. Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19. Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y Muscle Nerve; 2022 Nov; 66(5):593-602. PubMed ID: 36053970 [TBL] [Abstract][Full Text] [Related]
18. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC; JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266 [TBL] [Abstract][Full Text] [Related]
19. The frequency of ALSFRS-R reversals and plateaus in patients with limb-onset amyotrophic lateral sclerosis: a cohort study. Hu N; Shen D; Yang X; Cui L; Liu M Acta Neurol Belg; 2022 Dec; 122(6):1567-1573. PubMed ID: 35034333 [TBL] [Abstract][Full Text] [Related]